In myeloproliferative neoplasms, the potential benefits of detecting somatic gene variations include identifying the JAK2, CALR, and MPL driver mutations, detecting other genes such as ASXL1 that could provide prognostic information, aligning with targeted treatment options (e.g., TP53 and MDM2 inhibitors), and/or improving diagnostic categorization (e.g., SF3B1) [8,15]. This evidence concerns the gene JAK2 and myeloproliferative disorder.